SRSF2 is a serine/arginine-rich protein belonging to the family of SR proteins that are crucial regulators of constitutive and alternative pre-mRNA splicing. Although it is well known that phosphorylation inside RS domain controls activity of SR proteins, other post-translational modifications regulating SRSF2 functions have not been described to date. In this study, we provide the first evidence that the acetyltransferase Tip60 acetylates SRSF2 on its lysine 52 residue inside the RNA recognition motif, and promotes its proteasomal degradation. We also demonstrate that the deacetylase HDAC6 counters this acetylation and acts as a positive regulator of SRSF2 protein level. In addition, we show that Tip60 downregulates SRSF2 phosphorylation by inhibiting the nuclear translocation of both SRPK1 and SRPK2 kinases. Finally, we demonstrate that this acetylation/phosphorylation signalling network controls SRSF2 accumulation as well as caspase-8 pre-mRNA splicing in response to cisplatin and determines whether cells undergo apoptosis or G 2 /M cell cycle arrest. Taken together, these results unravel lysine acetylation as a crucial post-translational modification regulating SRSF2 protein level and activity in response to genotoxic stress.
Introduction
Pre-mRNA splicing consists of a highly regulated cascade of events that are critical for gene expression in higher eukaryotic cells. This process has emerged as an important mechanism of genetic diversity, as about 92-94% of human genes undergo alternative splicing, leading to the synthesis of various protein isoforms with different biological properties (Wang et al, 2008) . SRSF2 belongs to the serine/arginine-rich (SR) protein family, one of the most important class of splicing regulators that has a prominent role in splice-site selection, in multiples steps of spliceosome assembly as well as in both constitutive and alternative splicing (Long and Caceres, 2009 ). All members of the SR protein family share a modular organization and contain one or two N-terminal RNA recognition motifs (RRMs) that interact with the premRNA, and influence substrate specificity (Liu et al, 1998) , as well as a C-terminal SR sequence known as the RS domain that functions as a protein-protein interaction module (Wu and Maniatis, 1993) . Activity of SR proteins is highly regulated by extensive and reversible phosphorylation of serine residues inside RS domain. These phosphorylations modulate protein-protein interactions within the spliceosome and can influence RNA-binding specificity, splicing activity and subcellular localization. To date, numerous kinases phosphorylating SR proteins have been identified. They include the SRPK and CLK/STY family kinases that are highly specific for RS domain-containing splicing factors, the DNA topoisomerase I and AKT (Stamm, 2008) . However, data addressing the cellular signals that control phosphorylation of SR proteins remain scarce, as well as the specific kinases involved in these effects.
Chromatin biology and pre-mRNA splicing have been considered for a long time as two independent fields. However, recently, chromatin structure has been shown to affect both constitutive and alternative splicing, either through the recruitment of splicing factors (Sims et al, 2007) or through the modulation of RNA polymerase II elongation rate (Batsche et al, 2006) . In addition, two studies have demonstrated that DNA sequences associated with nucleosomes are preferentially located in exons (Schwartz et al, 2009; Tilgner et al, 2009) , providing a general concept for how the architecture of genome packaging could influence pre-mRNA splicing. Chromatin structure is highly controlled by post-translational modifications of histone protein tails including phosphorylation or acetylation. These modifications are catalysed by chromatin-modifying enzymes that add or remove specific groups in a reversible way. It was recently reported that two SR proteins, namely SRSF3 and SRSF1, bind histone H3 tail to control cell cycle progression (Loomis et al, 2009) . These data provide the first evidence that SR proteins associate with chromatin, and suggest that they could also be directly targeted by components of chromatin-remodeling complexes. Lysine acetylation is highly regulated through the opposite actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) enzymes. Besides histones, an increasing number of cellular proteins are also subjected to lysine acetylation (Yang and Seto, 2008) . Recently, a high-resolution mass spectrometry analysis revealed that a large number of acetylation sites are present on proteins implicated in splicing, including SR proteins, and identified the RRM as a major domain for acetylation (Choudhary et al, 2009) . These data support the idea that lysine acetylation could regulate the function of SR proteins.
In this study, we demonstrate for the first time that an acetylation/phosphorylation network controls the turnover and activity of the splicing factor SRSF2 in response to genotoxic stress. Therefore, besides phosphorylation, lysine acetylation also appears as a crucial post-translational modification of SR proteins.
Results

SRSF2, but not SRSF1, is acetylated by the HAT Tip60
To test whether SRSF2 could be acetylated, we first transfected SAOS2 cells with an expression vector encoding HA-tagged SRSF2 protein and used anti-HA antibody to immunoprecipitate SRSF2, the acetylated status of which was analysed by western blotting using an anti-acetyl-lysine antibody. As shown in Figure 1A , an acetylated form of SRSF2 was detected in these conditions. To go further, immunoprecipitation with anti-acetyl-lysine ( Figure 1B , left panel) or anti-SRSF2 ( Figure 1B , right panel) antibody was performed in nuclear-enriched extracts from H69 cells that express high levels of SRSF2. Again, an acetylated form of SRSF2 was detected by western blotting using an anti-SRSF2 or an antiacetyl-lysine antibody, respectively. Together, these data provide the first evidence that SRSF2 is subjected to acetylation. During the course of this study, we demonstrated that the Tip60 acetyltransferase controls acetylation of non-histone proteins in our cellular models (Leduc et al, 2006; Van Den Broeck, unpublished results) , and we postulated that SRSF2 could be a new Tip60 target. To test this hypothesis, an 'in vitro' acetyltransferase assay was set up in which various truncated GST-SRSF2 fusion proteins were used as putative substrates for the Tip60 acetyltransferase (His-Tip60 212-513 ) in the presence of [ 14 C]acetyl-CoA ( Figure 1C ). Of note, truncated fragments of SRSF2 were used in this assay, as full-length recombinant SRSF2 protein cannot be produced in bacteria. As detected by autoradiography ( Figure 1D , upper panel), recombinant Tip60 was able to efficiently acetylate SRSF2 on its first 60 amino acids (1-60) encompassing the RRM. This effect was specific of Tip60 as another acetyltransferase, namely GCN5, was unable to acetylate the GST-SRSF2(1-60) fragment (Figure 1D, upper panel) . No signal was detected with the GST-SRSF2(60-115) truncated fragment while a very faint signal, as compared with GST-SRSF2(1-60) fragment, was detected with the GST-SRSF2(115-221) truncated protein ( Figure 1D , upper panel), suggesting that SRSF2 could also be acetylated by Tip60 inside its RS domain part. By contrast, when the recombinant SRSF1 protein was used as an in vitro substrate of either Tip60 or GCN5 acetyltransferase, acetylation could not be detected (Supplementary Figure 1) . Although these results did not exclude the possibility that SRSF1 could also be subjected to acetylation (Choudhary et al, 2009) , they indicate that SRSF1 is not a substrate of Tip60 in vitro. In order to confirm these results 'in vivo', Tip60 was knocked down in H1299 cells and the acetylated status of endogenous SRSF2 was studied by immunoprecipitation using either an antiacetyl-lysine (Figure 1E, upper panel) or an anti-SRSF2 ( Figure 1E , lower panel) antibody followed by immunoblotting using an anti-SRSF2 or an anti-acetyl-lysine antibody, respectively. The data demonstrated that Tip60 neutralization significantly decreases SRSF2 acetylation in these cells. By contrast, and consistent with the in vitro experiments, acetylation of SRSF1 could not be detected when the membrane loaded with the anti-acetyl-lysine immunoprecipitates was re-blotted with an anti-SRSF1 antibody (Figure 1E, upper panel) . In addition, an interaction between both Tip60 and SRSF2 proteins was depicted in cells co-transfected with SRSF2-and Tip60-encoding plasmids ( Supplementary  Figure 2) , indicating that both proteins exist in a complex within these cells. Overall, these results demonstrate that SRSF2 is a substrate of the acetyltransferase Tip60. SRSF2(1-60) N-terminal part contains three lysine (K) residues (K17, K36 and K52; Figure 1F , upper panel). To map the acetylation site(s) targeted by Tip60 on SRSF2 inside its RRM domain, we produced recombinant mutated GST-SRSF2(1-60) fusion proteins in which each lysine was substituted by an arginine (R), a non-acetylable residue. Analysis of the K52R and K17R point mutants indicated that K52 was a prime-candidate site for Tip60-mediated acetylation as autoradiographic signal was dramatically lost when K52 residue was mutated into arginine ( Figure 1F , lower panel). Of note, we were not able to produce the GST-SRSF2(1-60) K36 point mutant in bacterial system, so we cannot exclude the possibility that K36 could be acetylated. Taken together, these results demonstrate that Tip60 acetylates SRSF2 on its K52 residue.
Acetylation by Tip60 controls SRSF2 protein turnover
To investigate the biological consequences of Tip60-mediated SRSF2 acetylation, we knocked down Tip60 expression by using two distinct siRNA in various carcinoma cell lines and monitored the expression level of SRSF2. Immunoblotting experiments reproducibly demonstrated that SRSF2 protein level significantly increased when Tip60 was neutralized as compared with control cells (Figure 2A and Supplementary Figure 3A ). This effect was specific of SRSF2 as SRSF1 protein amount was apparently not affected. This effect also mainly occurred at a post-transcriptional level as SRSF2 mRNA did not reproducibly increase under these conditions ( Figure 2A and Supplementary Figure 3B ). To confirm these results, rescue experiments were performed in which either the wild-type Tip60 or a mutant Tip60 with a defective HAT activity (Tip60 G380 ) was overexpressed in Tip60 knockout cells. As shown in Figure 2B , restoration of Tip60 expression in Tip60-deficient cells prevented SRSF2 protein accumulation while the mutant Tip60 G380 did not. Moreover, and consistent with Tip60 being a negative regulator of SRSF2, SRSF2 protein level decreased when cells were co-transfected with Tip60-encoding plasmid ( Figure 2C ). Interestingly, treating cells with the proteasomal inhibitor MG132 prevented SRSF2 downregulation in that case, thereby indicating that SRSF2 could be subjected to a Tip60-mediated proteasomal degradation. By contrast, co-transfection with the mutant Tip60 G380 -encoding plasmid had no significant effect on exogenous SRSF2 protein level ( Figure 2C ). Similar results were obtained when the effect of Tip60 or Tip60 G380 was assessed on endogenous SRSF2 protein level ( Figure 2D ). Taken together, these data support the notion that Tip60-mediated SRSF2 acetylation controls SRSF2 turnover. To assess the role of K52 in this setting, we generated an expression vector encoding an HA-tagged SRSF2(K52R) mutant protein harbouring a K52R substitution, thereby mimicking a non-Tip60-acetylable form of SRSF2. In co-transfection experiments, Tip60 as well as Tip60 G380 were unable to modify the level of the SRSF2(K52R) mutant ( Figure 2E HA-SRSF2 (K52R) protein was then analysed by immunoblotting. As depicted in Figure 2F , the mutant SRSF2(K52R) half-life was strongly enhanced as compared with that of wild-type SRSF2. When similar experiments were performed in HA-Tip60-transfected cells, Tip60 was found to reduce the half-life of HA-SRSF2 protein, while it did not affect that of the HA-SRSF2(K52R) mutant (Supplementary Figure 4) . Overall, these results demonstrate that acetylation of SRSF2 by Tip60 negatively controls the expression level of the SRSF2 protein by a mechanism involving the proteasome pathway.
The deacetylase HDAC6 positively controls SRSF2 protein level Lysine acetylation is finely regulated by the equilibrium between acetyltransferase and deacetylase activities. Among HDACs, HDAC6 is unique as it possesses intrinsic ubiquitinlinked functions, in addition to its deacetylase activity (Seigneurin-Berny et al, 2001; Boyault et al, 2006) , and has been reported to protect ubiquitinated proteins from subsequent processing by the proteasome (Boyault et al, 2006 (Boyault et al, , 2007b . Having demonstrated that acetylation controls SRSF2 protein turnover via a proteasome-dependent mechanism, we investigated the role of HDAC6. First, HA-tagged SRSF2 was expressed in the presence or absence of HDAC6. As shown in Figure 3A , overexpressing HDAC6 induced a strong accumulation of SRSF2 protein without affecting its mRNA level (Supplementary Figure 5A) . Conversely, neutralizing HDAC6 by using siRNA significantly decreased SRSF2 protein expression, but not SRSF2 mRNA or SRSF1 protein level ( Figure 3B and data not shown). Overall, these data indicated that HDAC6 positively controls SRSF2 expression level. In addition, both HDAC6 and SRSF2 proteins were found to coimmunoprecipitate (Supplementary Figure 5B) . To investigate the role of K52 in this setting, we generated an anti-Ac-K52 SRSF2 antibody recognizing SRSF2 acetylated onto K52 (Supplementary Figure 6) . Immunoprecipitation experiments of acetylated K52-SRSF2 were carried out in cells deprived of HDAC6 followed by immunoblotting directed against SRSF2. The results showed that knocking down HDAC6 induced the accumulation of an acetylated form of SRSF2 ( Figure 3C , upper panel). Interestingly, HDAC6 was unable to stabilize the mutant SRSF2(K52R) as compared with the wild-type SRSF2 protein ( Figure 3C , middle panel). In addition, the knockdown of HDAC6 in cells overexpressing either the SRSF2 or mutant SRSF2(K52R) construct severely decreased wild-type SRSF2 protein level while it had no effect on SRFS2(K52R) protein expression ( Figure 3C , lower panel). Taken together, these results indicate that HDAC6 targets K52 to positively control SRSF2 protein expression. To extend these data, we took advantage of 3T3 cell lines, previously established from mouse embryo fibroblasts isolated from parental (WT) or HDAC6-deficient (KO) mice, in which wild-type HDAC6 was re-expressed ( þ WT; Boyault et al, 2007b) and analysed the expression of murine SRSF2 by immunoblotting. As expected from the above data, SRSF2 protein level was significantly decreased in HDAC6À/À 3T3 as compared with parental cells, and reintroduction of wildtype HDAC6 in knockout cells restored the basal level of SRSF2 protein ( Figure 3D , upper panel). HDAC6 is a unique class II deacetylase which contains two catalytic domains, and a C-terminal zinc finger domain (ZnF-UBP) that binds with high-affinity free ubiquitin as well as mono-and polyubiquitinated proteins (Boyault et al, 2007a) . To characterize the functional domains of HDAC6 involved in SRSF2 regulation, we monitored the expression of SRSF2 in 3T3 cells derived from HDAC6-deficient mice re-expressing either the wild-type HDAC6 ( þ WT), the HDAC6 mutant deprived of deacetylase activity ( þ HD m ) or the HDAC6 mutant deprived of ubiquitin-binding function ( þ Ub m ). The results showed that both mutants were unable to rescue the downregulation of SRSF2 on HDAC6 loss as compared with wild-type HDAC6 ( Figure 3D , lower panel). In addition, HDAC6 was absolutely required for the accumulation of SRSF2 in 3T3 cells treated with MG132 ( Figure 3E ). This effect was dependent on both the catalytic activity and the ability of HDAC6 to bind ubiquitin. Overall, these results demonstrate that HDAC6 is a key factor of SRSF2 protein turnover and identify the crucial role of its catalytic and ubiquitin-binding domains in this setting. Finally, as the ratio between Tip60 and HDAC6 proteins could be a determinant of SRSF2 expression, we performed co-transfection experiments in which increasing amounts of HDAC6 were produced in the presence of high levels of Tip60. As shown in Figure 3F (upper panel), HDAC6 thoroughly reversed Tip60-mediated downregulation of SRSF2, even at a low level, indicating that HDAC6 activity outweighs the negative regulation of SRSF2 imposed by Tip60. By contrast, and consistent with K52 being a key residue in this setting, HDAC6 did not affect the expression level of SRSF2(K52R) in cells overexpressing Tip60 ( Figure 3F , lower panel). As a whole, our data support a model in which HDAC6 has a key role in the maintenance of SRSF2 protein level by inhibiting Tip60-mediated acetylation and proteasomal degradation. These results are the first evidence that an acetylation/deacetylation switch controls SRSF2 protein turnover.
Tip60 inhibits SRSF2 phosphorylation by preventing SRPK1 and SRPK2 nuclear translocation
Numerous studies have now identified cross talks between lysine acetylation and others post-translational modifications, such as phosphorylation (Yang and Seto, 2008) . As phosphorylation is a critical regulator of the activity of SR proteins, we then asked whether acetylation could affect the phosphorylation status of SRSF2. To explore this possibility, we used two different antibodies recognizing phosphorylated forms of SRSF2 ( Figure 4A and Supplementary Figure 7) and we first analysed the phosphorylation level of SRSF2 in cells transfected with a plasmid encoding Tip60-HA, in the presence of MG132 to prevent SRSF2 proteasomal degradation. Overexpression of Tip60 significantly attenuated SRSF2 phosphorylation ( Figure 4A ). The effect of Tip60 required its HAT activity as SRSF2 phosphorylation was not affected by mutant Tip60 G380 . To confirm these results, HA-tagged SRSF2 protein was overexpressed together with or without Tip60 in cells treated with MG132, and its phosphorylated status was assessed after immunoprecipitation with an anti-HA antibody followed by immunoblotting using the anti-phospho SRSF2 antibody. As shown in Figure 4B , Tip60 overexpression strongly decreased the phosphorylation of SRSF2. In addition, phospho-SRSF2 protein level was enhanced when Tip60 was neutralized by siRNA ( Figure 4C ). Altogether, these data indicate that Tip60 negatively controls SRSF2 phosphorylation and suggest a dialogue between acetylation and phos-phorylation networks to control SRSF2 protein activity. Among the growing list of SR protein kinases, the SRPK family that includes SRPK1 and SRPK2 is well characterized. Interestingly, we provided evidence that downregulation of either SRPK1 or SRPK2 protein attenuated SRSF2 phosphorylation, whereas treatment with TG003, a pharmacological inhibitor of CLK/STY, another SR-phosphorylating kinase, had no effect (Supplementary Figure 8) . Overall, these data indicate that both SRPK1 and SRPK2 kinases largely contribute to SRSF2 phosphorylation in our cellular models. Therefore, to test whether Tip60 could prevent SRSF2 phosphorylation by altering the expression level of SRPK(s), we performed immunoblotting experiments using whole-cell extracts of cells in which Tip60 expression was either upregulated or knocked down. As shown in Figure 4D and E (upper panels), overexpression or neutralization of Tip60 did not significantly modify the total amount of SRPK1 or SRPK2 protein. SRPK1 and SRPK2 kinases are proteins that shuttle between the cytoplasm and the nucleus (Ding et al, 2006) . So, we next tested whether Tip60 could alter SRPK(s) subcellular distribution. To this purpose, cellular fractionation experiments were set up in cells transfected with either Tip60-encoding plasmid or Tip60 siRNA, and SRPK protein levels were analysed by immunoblotting in nuclear or cytoplasmic fractions. A significant decrease of nuclear SRPK(s) correlated with a decreased level of nuclear phosphorylated SRSF2 protein (P-SRSF2) protein was observed on Tip60 overexpression as compared with control cells ( Figure 4D , lower panel). By contrast, strong nuclear accumulation of SRPK(s) associated with P-SRSF2 increase was observed in cells knocked down for Tip60 as compared with mismatch transfected cells ( Figure 4E , lower panel). To confirm these results, immunofluorescence studies were set up. As shown in Figure 4F , the nuclear amount of both SRPK1 and SRPK2 proteins increased in cells deprived of Tip60 as compared with mismatch transfected cells. Conversely, a slight but reproducible decrease of both SRPK1 and SRPK2 nuclear staining was observed in cells overexpressing Tip60, whereas this effect was not observed with the mutant Tip60 G380 (Supplementary Figure 9) . Altogether, these results indicate that Tip60 negatively controls SRSF2 phosphorylation and the nuclear accumulation of SRPK kinases, by a mechanism requiring its HAT activity. Of note, HDAC6 neither affected SRSF2 phosphorylation status, nor modified SRPK(s) protein levels or subcellular localization in our cellular models (data not shown).
SRSF2 accumulates in a hypoacetylated/ phosphorylated form in response to cisplatin treatment
We finally attempted to characterize in which physiological context the signalling networks involving Tip60, HDAC6 and SRPK(s) proteins controlled SRSF2 protein status. We recently demonstrated that SRSF2 was upregulated and required for the apoptotic response induced by alkylating agents (Merdzhanova et al, 2008) . In this study, we provided evidence that SRSF2 also accumulates following cisplatin treatment ( Figure 5A , left panel). As quantitative RT-PCR experiments failed to detect an increase of SRSF2 mRNA level in treated cells (Supplementary Figure 10A) , the accumulation of SRSF2 protein in response to cisplatin is mainly a posttranscriptional event. In addition, inhibition of SRSF2 expression strongly impaired the occurrence of apoptosis induced by cisplatin ( Figure 5A ). The use of a distal 5 0 splice donor site of exon 8 in the human caspase-8 mRNA leads to the synthesis of an alternative splice variant, caspase-8L, a competitive inhibitor of caspase-8 (Himeji et al, 2002) . In our cells, cisplatin decreased the caspase-8L/caspase-8a ratio ( Figure 5B ). This effect was prevented when SRSF2 was neutralized, indicating that SRSF2 is involved in caspase-8 pre-mRNA splicing on cisplatin treatment. Of note, caspase-8 was required for apoptosis in this setting, as co-treating cells with cisplatin and the specific cell-permeable caspase-8 inhibitor IETD-CHO significantly decreased the number of apoptotic cells and prevented the decrease of the caspase-8L/caspase-8a ratio (Supplementary Figure 10C and D) . Taken together, these results indicate that SRSF2 accumulates on cisplatin treatment and contributes to cisplatin-induced apoptosis. To assess whether acetylation/phosphorylation signalling networks could have a role in this context, we first analysed the acetylated status of SRSF2. Immunoprecipitation experiments demonstrated that SRSF2 acetylation was dramatically lost on cisplatin treatment ( Figure 5C ). This effect was specific of SRSF2 as cisplatin strongly stimulated the acetylation of the transcription factor E2F1, in agreement with previous data (Ianari et al, 2004) . Consistent with the loss of SRSF2 acetylation, immunoblotting and quantitative RT-PCR experiments demonstrated that cisplatin induced a significant decrease of both Tip60 mRNA and protein levels as compared with untreated cells, which correlated with the occurrence of apoptosis as detected by caspase-3 activation ( Figure 5D ). These results were also confirmed in H358 cells (Supplementary Figure 10B) . It was recently shown that the circadian transcription factor Clock controls Tip60 gene expression in human lung carcinoma cell lines, and that high levels of both Clock and Tip60 proteins correlate with resistance to cisplatin (Miyamoto et al, 2008) . Interestingly, we observed that downregulation of Tip60 mRNA and protein on cisplatin-induced apoptosis was associated with the decrease of Clock protein level ( Figure 5D ). As cisplatin did not affect Tip60 mRNA stability as measured after actinomycin D treatment (Supplementary Figure 11) , our results suggest that Clock might be involved in the decrease of Tip60 gene expression following cisplatin exposure. Moreover, while expression of HDCA6 protein did not significantly vary in response to cisplatin, its neutralization strongly prevented the accumulation of SRSF2 ( Figure 5E , upper panel), indicating that HDAC6 is involved in SRSF2 increase in that case. These results were confirmed in 3T3 cells ( Figure 5E, lower panel) . Finally, and concomitant with the loss of SRSF2 acetylation, increased levels of P-SRSF2 were detected in response to cisplatin ( Figure 5F ) and were associated with the nuclear accumulation of both SRPK1 and SRPK2 kinases, as detected using both subcellular fractionation experiments ( Figure 5G ) and immunofluorescence studies (Supplementary Figure 12) . Overall, these results demonstrate that cisplatin induces the accumulation of a hypoacetylated and phosphorylated form of SRSF2, by a mechanism involving the Tip60, HDAC6, SRPK1 and SRPK2 proteins. Anti-a-tubulin and anti-histone H3 antibodies were used to assess the fractionation efficiency. (E) H810 cells were transfected for 72 h with mismatch or Tip60(1) siRNAs. Total cellular extracts were immunoblotted with anti-SRPK1 or anti-SRPK2 antibody (upper panel). Cytoplasmic (C) and nuclear (N) extracts were subjected to immunoblotting using the indicated antibodies. (lower panel; F) H810 cells were transfected for 72 h with mismatch or Tip60(2) siRNA. Immunolocalization of either SRPK1 or SRPK2 protein (green) was visualized by immunofluorescence. DAPI staining (blue) was used to counterstain nuclei.
we investigated the role of each SRPK in cisplatin-induced SRSF2 phosphorylation and apoptosis. For this purpose, H358 ( Figure 6 ) and H1299 (data not shown) cells were transfected with siRNA targeting either SRPK1 or SRPK2, and were subjected or not to cisplatin exposure for 24 h. We observed that neutralization of SRPK2 significantly prevented the phosphorylation of SRSF2 ( Figure 6A, left panel) and the induction of apoptosis following cisplatin treatment RT-PCR analysis using specific primers of caspase-8 splice variants. Gapdh was used as an internal control (left panel). Densitometric signals were quantified using the Image J software and the relative ratio caspase-8L/caspase-8a was calculated in either untreated (grey bars) or treated (black bars) cells (right panel). (C) H810 cells were treated or not for 24 h with 100 mM cisplatin. Nuclear-enriched extracts were prepared and immunoprecipitation (IP) of acetylated proteins was performed using an anti-acetyl-lysine (Ac-K) antibody followed by immunoblotting using either an anti-SRSF2 or anti-E2F1 antibody. (D) H810 cells were treated or not for 24 h with 100 mM cisplatin and subjected to western blot analysis (left panel). Tip60 transcript level was quantified by quantitative RT-PCR (right panel). (E) H358 cells were transfected for 48 h with mismatch or HDAC6 siRNAs and treated ( þ ) or not (À) for an additional 24 h with 100 mM cisplatin. Western blot analysis was performed for the detection of SRSF2 or HDAC6 protein (upper panel). Wild-type or HDAC6 knockout 3T3 cells were treated ( þ ) or not (À) with 100 mM cisplatin for 24 h and SRSF2 protein level was assessed by immunoblotting (lower panel). (F) Total cellular extracts were obtained from H358 and H1299 cells treated or not for 24 h with 100 mM cisplatin. Phosphorylated SRSF2 protein (P-SRSF2) and SRSF2 protein levels were analysed by western blotting. (G) Cytoplasmic and nuclear extracts from H810 cells treated or not for 24 h with 100 mM cisplatin were subjected to western blotting.
( Figure 6A , left and right panels). Of note, and as shown by western blotting ( Figure 6A , left panel), exposure to cisplatin led to the appearance of a cleaved product of SRPK2 that has been previously described in apoptotic cells (Kamachi et al, 2002) . In addition, and consistent with apoptosis measurements, the knockdown of SRPK2 strongly increased the caspase-8L/caspase-8a ratio in cisplatin-treated cells ( Figure 6B ). Similar results were obtained in H1299 cells (data not shown).
Altogether, these results demonstrate that SRPK2 is a critical regulator of SRSF2 during cisplatin-induced apoptosis. By contrast, the neutralization of SRPK1 did not prevent the accumulation of P-SRSF2, and apoptosis sharply increased as detected by western blot ( Figure 6A , left panel) or flow cytometry ( Figure 6A, right panel) . These data indicate that SRPK1 inhibits rather than stimulates cisplatin-induced apoptosis. Therefore, it appears that SRPK1 and SRPK2 kinases do not have the same role in response to cisplatin. Finally, as apoptosis was impaired in SRPK2-depleted cells on drug treatment, we wondered about the fate of these cells. To answer, the cell cycle distribution was analysed by flow cytometry. As depicted in Figure 6C , while appearance of apoptotic cells with a sub-G 1 DNA content was observed after cisplatin exposure, inhibiting SRPK2 expression in these conditions induced a G 2 /M arrest. Overall, these data indicate that SRPK-regulated SRSF2 phosphorylation controls cell fate decision in response to cisplatin treatment.
Discussion
A high-resolution mass spectrometry analysis recently identified 3600 lysine acetylation sites on 1750 proteins (Choudhary et al, 2009) . Interestingly, when these proteins were classified according to their cellular functions, two classes emerged: the first one bringing together cell cycle regulators and the second one, RNA-splicing components. Moreover, when the architecture of acetylated proteins was analysed, RRM domains were overrepresented in the lysine acetylome, strongly supporting a role of this post-translational modification in the control of pre-mRNA processing events. In this study, we unravel the first acetylation/phosphorylation signalling network regulating the turnover and activity of a key splicing regulator, namely the SR protein SRSF2. In this setting, we identify a closed interplay among SRSF2, the Tip60 acetyltransferase, the HDAC6 deacetylase, and the SRPK1 and SRPK2 kinases. Therefore, besides phosphorylation, we characterize lysine acetylation as a new posttranslational modification of SR proteins, whose role as a regulator of pre-mRNA splicing events has now to be fully considered.
Only a few data exist about the molecular mechanisms regulating SRSF2 protein expression. It is known that, when highly expressed, SRSF2 negatively controls its own expression, through activation of alternative splicing events leading to the generation of distinct splice variants that are targeted by the non-sense-mediated mRNA decay machinery (Sureau et al, 2001 ). In addition, we recently showed that E2F1 is a direct transcriptional factor towards SRSF2 promoter (Merdzhanova et al, 2008) . In this study, we demonstrate that Tip60 acetylates SRSF2 on its lysine 52 (K52) residue and promotes its proteasomal degradation, thereby characterizing a novel mechanism that controls SRSF2 protein level. K52 appears to be a critical residue for proteasome targeting, as its substitution by arginine significantly enhances the half-life of a mutant SRSF2(K52R). It has been previously shown that SRSF2 partially co-localizes with proteasomes and accumulates under treatment with the proteasome inhibitor lactacystin (Dino Rockel and von Mikecz, 2002; Baldin et al, 2008) . SRSF6 is also targeted by the proteasome (Lai et al, 2003) . Therefore, these and our data suggest that proteasome-dependent proteolysis could be a general mechanism to control turnover of SR proteins. Most of the examples described in the literature designate lysine acetylation as a stabilizing post-translational modification, through a blocking effect which hinders lysine ubiquitination (Sadoul et al, 2008) . In contrast and consistent with our results, lysine acetylation has also been reported as a signal enhancing protein degradation (Caron et al, 2005; Leduc et al, 2006; Sadoul et al, 2008) . We do not elucidate here the molecular mechanisms by which Tip60 targets SRSF2 to proteasomal degradation. Notably, we do not provide evidence that SRSF2 is ubiquitinated on Tip60 overexpression. As previously shown for p53 (Asher et al, 2002 (Asher et al, , 2005 , it is possible that SRSF2 is degraded by an ubiquitin-independent proteasomal pathway. However, as Tip60 can interact with some E3-ubiquitin ligases such as MDM2 (Legube et al, 2002) or Pirh2 (Logan et al, 2004) , it is tempting to speculate that Tip60 could act as an adaptor to allow the recruitment and to stimulate the activity of specific ubiquitin ligase complex towards SRSF2. Furthermore, we demonstrate that the deacetylase HDAC6 interacts with and stabilizes SRSF2 by a mechanism requiring both its deacetylase and ubiquitin-binding domains, thereby strongly suggesting a role of ubiquitination in the control of SRSF2 protein turnover. Again, lysine 52 is a critical residue in this process as the mutant SRSF2(K52R) is insensitive to HDAC6 expression. Therefore, these results suggest that deacetylation of SRSF2 by HDAC6 could prevent its further ubiquitination and degradation. Alternatively, as high-affinity binding of HDAC6 to ubiquitin prevents the access of other cellular factors to polyubiquitin chains, and protects ubiquitinated proteins from proteasomal degradation (Boyault et al, 2007a) , HDAC6 could bind an acetylated and ubiquitinated form of SRSF2 and prevent its further degradation. This could explain why SRSF2 still accumulates in cells overexpressing Tip60 in the presence of high amounts of HDAC6 ( Figure 3F ) and supports a model in which the equilibrium between Tip60 and HDAC6 activities controls SRSF2 protein turnover ( Figure 7A ). Further experiments are now needed to more thoroughly examine the relationship between SRSF2 and the components of the ubiquitination machinery.
Phosphorylation of SR proteins is essential for their nuclear import and is required for initiation of spliceosome assembly (Cao et al, 1997; Xiao and Manley, 1997) . Conversely, dephosphorylation of SR proteins is critical for splicing catalysis once the spliceosome is assembled (Mermoud et al, 1992; Cao et al, 1997) and for several post-splicing events (Sanford et al, 2005) . Therefore, phosphorylation of SR proteins must be tightly regulated. Several SR protein kinases have been identified to date. The SRPK1 and SRPK2 kinases are among the best-characterized ones. They are detected in both the cytoplasm and the nucleus (Wang et al, 1998; Ding et al, 2006) and have an important role in nuclear import as well as in intranuclear localization of SR proteins (Gui et al, 1994; Yeakley et al, 1999) . SRPKs are major kinases for SR proteins in mammalian cells (Hayes et al, 2006) . Consistently, we provide evidence that both SRPK1 and SRPK2 proteins are the main regulators of SRSF2 phosphorylation in our cellular models. Moreover, we demonstrate that Tip60 decreases the phosphorylation acetylates SRSF2 on its lysine 52 residue and prevents SRPK1 and SRPK2 nuclear localization. SRSF2 accumulates in a hyperacetylated/hypophosphorylated form that is subjected to proteasomal degradation. This effect is counterbalanced by the HDAC6 deacetylase, which positively controls SRSF2 protein level by deacetylating SRSF2 and preventing its proteasomal degradation. (B) On cisplatin treatment, Tip60 protein level strongly decreases leading to the nuclear accumulation of both SRPK1 and SRPK2 kinases, to the stabilization of SRSF2 in a hypoacetylated/phosphorylated form by a mechanism involving HDAC6. SRSF2 and SRPK2 cooperate to induce apoptosis through regulation of the splicing switch of caspase-8 pre-mRNA. In contrast, SRPK1 appears to act as an antiapoptotic factor. In the absence of SRPK2, apoptosis is blocked and treated cells accumulate in G 2 /M phase indicating that SRPKmediated SRSF2 phosphorylation controls cell fate decision.
of SRSF2 by a mechanism requiring its HAT activity, unravelling a close interplay between acetylation and phosphorylation signalling pathways. It has been recently proposed, in the same way that phosphorylation affects acetylation of a neighbouring lysine, that acetylation might also regulate phosphorylation of adjacent or distant residues (Yang and Seto, 2008) . In addition recent studies have shown that, although recognition of the RS domain of SRSF1 by a docking groove on SRPK1 is sufficient to initiate processive and directional phosphorylation, continued phosphorylation relies on the fine-tuning of contacts with RRM modules Ngo et al, 2008) . On the basis of these data, it might be speculated that acetylation of SRSF2 inside its RRM by Tip60 could interfere with SRPK-mediated phosphorylation. However, as HDAC6 as well as the mutation of lysine 52 into a non-acetylable residue do not modify SRSF2 phosphorylation (V Edmond, unpublished results), acetylation is probably not involved in the inhibition of SRSF2 phosphorylation by Tip60. Consistent with such hypothesis, we provide further evidence that Tip60, but not its inactive catalytic mutant Tip60 G380 , inhibits the nuclear translocation of both SRPK1 and SRPK2 kinases. These data indicate that an inappropriate subcellular distribution of SRPKs might mainly contribute to the negative effect of Tip60 on SRSF2 phosphorylation. It has been shown that the spacer sequence that splits the conserved kinases domains of SRPK1 and SRPK2 into two blocks is involved in their partitioning between the cytoplasm and the nucleus (Ding et al, 2006) . Whether Tip60 could directly or indirectly target this accessory domain to affect nuclear accumulation of SRPKs remains to be determined. Of note, SRPK1 was identified as a putative acetylated protein by Choudhary et al (2009) thereby suggesting that Tip60 could at least acetylate SRPK1 to control its subcellular distribution. However, as signalling pathways involving the major molecular chaperone HSP90 (Zhong et al, 2009) or AKT (Jang et al, 2009) were recently found to control SRPK1/2 subcellular partitioning, additional experiments are required to explore the effects of Tip60 on these processes.
In agreement with an important role of SRSF2 during DNA Damage Response (DDR; Merdzhanova et al, 2008 ), we finally demonstrate that SRSF2 is upregulated and required for cellular apoptosis in response to cisplatin treatment. Importantly, we show that, in this context, SRSF2 accumulates in a phosphorylated/hypoacetylated form. Such posttranslational modifications of SRSF2 are accompanied by a strong decrease of Tip60 mRNA and protein expression, as well as with the nuclear accumulation of both SRPK1 and SRPK2 kinases. The crucial role of Tip60 during DDR is now emerging (Squatrito et al, 2006) and high amounts of Tip60 protein have been correlated with cisplatin resistance in several human lung carcinoma cell lines (Miyamoto et al, 2008) . Therefore, our results are consistent with a model in which cisplatin-induced apoptosis involves Tip60 downregulation, SRSF2 stabilization and SRSF2 phosphorylation ( Figure 7B ). In addition, as HDAC6 is required for SRSF2 stabilization ( Figure 5E ) as well as for apoptosis occurrence (data not shown) in this context, the Tip60/HDAC6 ratio would have a key role in the control of SRSF2 expression in response to cisplatin. Moreover, we also demonstrate that SRPK2 is absolutely required for SRSF2 phosphorylation and cisplatin-induced apoptosis. In contrast, SRPK1 appears to have opposite functions as its neutralization increases rather than inhibits apoptosis. Of note, such a role of SRPK1 in resistance to cisplatin has been previously reported in pancreatic carcinoma (Hayes et al, 2006 (Hayes et al, , 2007 . Therefore, and as recently suggested (Mathew et al, 2008) , our data provide further evidence that each SRPK has both overlapping and independent functions. Furthermore, they support a critical role of SRPK2-mediated SRSF2 phosphorylation in the induction of apoptosis following cisplatin treatment.
To conclude, our study highlights a new acetylation/phosphorylation signalling network targeting the SRSF2 protein, to control cellular apoptosis in response to genotoxic stress. These data reinforce the connection between chromatin and splicing players, and open the way to further experiments aiming at thoroughly examining the role of such connection in the control of pre-mRNA splicing events.
Materials and methods
Cell lines, cell treatments, plasmids and transfection H358, H1299, H810, H69 human lung carcinoma cell lines and SAOS2 osteosarcoma cells were cultured as described (Salon et al, 2007; Merdzhanova et al, 2008) . Stable inducible SRSF2 clones derived from H358 cells were obtained using a modified tetracyclinregulated inducible expression system (Tet-On System, Clontech, Ozyme, Saint Quentin en Yvelines, France) as previously described (Salon et al, 2006) . The parental and HDAC6À/À 3T3 cell lines, as well as the 3T3 cell lines derived from HDAC6-deficient cells reexpressing wild-type HDAC6 ( þ WT) or HDAC6 bearing mutations either in the two catalytic deacetylase domains (HD m ) or in the ZnF-UBP ubiquitin-binding domain (Ub m ) have been previously described (Boyault et al, 2007b) . They were maintained in DMEM (GibcoBRL) supplemented with 10% (v/v) heat-inactivated FCS, 2 mM L-glutamine and 100 U/ml penicillin/streptomycin in 5% CO 2 at 371C. Plasmids and reagents used in this study are described in detail in the Supplementary data.
Immunoprecipitation and western blotting experiments
Immunoprecipitation and western blotting experiments were performed as previously described (Salon et al, 2006) . All the antibodies used in this study are described in the Supplementary data. Cellular fractionation experiments were performed as described in the Supplementary data.
In vitro acetylation assays
Distinct cDNA encoding truncated forms of SRSF2 protein were fusionned in frame with GST by subcloning into pGEX-6P3 plasmid. Beads coated with GST, GST-SRSF2(1-60), , or GST-SRSF1 fusion proteins were prepared according to the manufacturer's protocol (Bulk GST Purification module, Pharmacia Biotech). 'In vitro' acetyltransferase assays were performed using 2 mg of each recombinant GST-SRSF2 fusion peptides, 1 mg of recombinant His-tagged Tip60 212-513 or His-tagged GCN5 protein and 0.05 mCi of [ 14 C]acetyl-CoA, as described previously (Leduc et al, 2006) .
Transfection of siRNA oligonucleotides
The sequences designed to specifically target human SRSF2, Tip60, HDAC6, srpk1 and srpk2 RNAs are listed in the Supplementary data. Cells were transfected with siRNA oligonucleotides duplex using Oligofectamine reagent according to the manufacturer's instructions (Invitrogen, Cergy Pontoise, France), excepted for H810 cells transfected with Hi-Perfect reagent (Qiagen). The cells were analysed 72 h after transfection.
Quantitative RT-PCR and RT-PCR analyses
Quantitative RT-PCR was performed on Stratagene MX3005P apparatus (Agilent Technologies), as previously described (Van Den Broeck et al, 2008) . The specific primers used for mRNA amplification are described in the Supplementary data. RT-PCR
